DE60237115D1 - Synergistische Kombination von (-) -Gossypol mit Docetaxel oder Paclitaxel zur Behandlung von Krebs. - Google Patents

Synergistische Kombination von (-) -Gossypol mit Docetaxel oder Paclitaxel zur Behandlung von Krebs.

Info

Publication number
DE60237115D1
DE60237115D1 DE60237115T DE60237115T DE60237115D1 DE 60237115 D1 DE60237115 D1 DE 60237115D1 DE 60237115 T DE60237115 T DE 60237115T DE 60237115 T DE60237115 T DE 60237115T DE 60237115 D1 DE60237115 D1 DE 60237115D1
Authority
DE
Germany
Prior art keywords
bcl
gossypol
cancer
docetaxel
paclitaxel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237115T
Other languages
English (en)
Inventor
Shaomeng Wang
Dajun Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
University of Michigan
Original Assignee
Georgetown University
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University, University of Michigan filed Critical Georgetown University
Application granted granted Critical
Publication of DE60237115D1 publication Critical patent/DE60237115D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
DE60237115T 2001-05-30 2002-05-30 Synergistische Kombination von (-) -Gossypol mit Docetaxel oder Paclitaxel zur Behandlung von Krebs. Expired - Lifetime DE60237115D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29398301P 2001-05-30 2001-05-30
PCT/US2002/017206 WO2002097053A2 (en) 2001-05-30 2002-05-30 Small molecule antagonists of bcl2 family proteins

Publications (1)

Publication Number Publication Date
DE60237115D1 true DE60237115D1 (de) 2010-09-02

Family

ID=31495521

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237115T Expired - Lifetime DE60237115D1 (de) 2001-05-30 2002-05-30 Synergistische Kombination von (-) -Gossypol mit Docetaxel oder Paclitaxel zur Behandlung von Krebs.

Country Status (18)

Country Link
US (1) US20030008924A1 (de)
EP (1) EP1474121B1 (de)
JP (1) JP2005515158A (de)
KR (1) KR20040108528A (de)
CN (1) CN1589135A (de)
AT (1) ATE474568T1 (de)
AU (1) AU2002305769B2 (de)
CA (1) CA2449245A1 (de)
DE (1) DE60237115D1 (de)
ES (1) ES2349349T3 (de)
HK (1) HK1071066A1 (de)
IL (1) IL159110A0 (de)
MX (1) MXPA03010977A (de)
NO (1) NO20035301D0 (de)
NZ (1) NZ529792A (de)
SG (1) SG157952A1 (de)
WO (1) WO2002097053A2 (de)
ZA (1) ZA200309306B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20023357D0 (no) * 2002-04-19 2002-07-11 Amersham Health As Blanding
US20070060615A1 (en) * 2003-02-18 2007-03-15 University Of South Florida Method of Modulating Apoptosis Through Modulation of E2F1
DE602004028880D1 (de) * 2003-06-25 2010-10-07 Burnham Inst La Jolla Analoga von Apogossypol zur Verwendung in der Behandlung von Krebs
WO2005094804A1 (en) * 2004-03-25 2005-10-13 The Regents Of The University Of Michigan Gossypol co-crystals and the use thereof
BRPI0511070A (pt) 2004-06-17 2007-11-27 Infinity Pharmaceuticals Inc compostos e processos para inibição da interação de proteìnas bcl com parceiros de ligação
US7842815B2 (en) * 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US20060144723A1 (en) * 2004-11-02 2006-07-06 Mary Fuller Device for securing valuables
JP2008533039A (ja) * 2005-03-11 2008-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 抗アポトーシスＢｃｌ−２ファミリーメンバーのクロメン−４−オン阻害剤およびその使用
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
US7557251B2 (en) * 2006-03-30 2009-07-07 The Regents Of The University Of Michigan Production of gossypol co-crystals
CA2649877A1 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
US7857804B2 (en) 2006-09-01 2010-12-28 Mccaffrey Timothy A Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders
US20090030088A1 (en) * 2007-04-20 2009-01-29 Clemson University Therapeutic benefits of gossypol, 6-methoxy gossypol, and 6,6'-dimothxy gossypol
WO2009036035A1 (en) * 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors
WO2009052443A1 (en) * 2007-10-19 2009-04-23 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
EP2323648A4 (de) * 2008-08-14 2012-10-03 Uab Research Foundation Mittel gegen arrhythmie, anwendungsverfahren, identifizierungsverfahren und kits dafür
ES2668837T3 (es) * 2008-12-11 2018-05-22 Abraxis Bioscience, Llc Terapia de combinación que incluye un taxano y un agente terapéutico adicional
WO2011044375A2 (en) * 2009-10-08 2011-04-14 Sanford-Burnham Medical Research Institute Apogossypolone derivatives as anticancer agents
CA2804795A1 (en) 2010-07-12 2012-01-19 Nicholas Vrolijk Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US8945627B2 (en) 2011-05-05 2015-02-03 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
CN103958508B (zh) * 2011-10-14 2019-02-12 艾伯维公司 用于治疗癌症以及免疫与自身免疫性疾病的细胞凋亡诱导剂
JP2015503516A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
EP2794592A1 (de) 2011-12-23 2014-10-29 Novartis AG Verbindungen zur hemmung der interaktion von bcl2 mit bindungspartnern
EP2794591A1 (de) 2011-12-23 2014-10-29 Novartis AG Verbindungen zur hemmung der interaktion von bcl2 mit bindungspartnern
AU2012355613A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
JP2015503517A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
WO2015123617A1 (en) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Method for reducing bcl2 gene expression
EP3708170A1 (de) 2014-05-05 2020-09-16 BioVentures, LLC Zusammensetzungen und verfahren zur hemmung von antiapoptotischen bcl-2-proteinen als anti-aging mittel
AU2015292710A1 (en) 2014-07-22 2017-02-16 Bioventures, Llc. Compositions and methods for selectively depleting senescent cells
CN105884634B (zh) * 2015-01-05 2019-06-04 南开大学 棉酚衍生物和它们的制备,在农药上的应用及抗癌活性
US11098021B2 (en) 2015-08-12 2021-08-24 Memorial Sloan-Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
US20180335421A1 (en) * 2015-11-20 2018-11-22 Memorial Sloan-Kettering Cancer Center Method for screening inhibitors targeting anti-apoptotic survival pathways
WO2017142348A1 (ko) * 2016-02-18 2017-08-24 연세대학교 산학협력단 폴리페놀 화합물을 유효성분으로 포함하는 암 치료용 약학조성물
CN108697667A (zh) 2016-02-18 2018-10-23 延世大学校产学协力团 用于治疗癌症、含有多酚化合物作为活性成分的药物组合物
JP6936498B2 (ja) 2016-04-21 2021-09-15 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用
CN109718377B (zh) * 2017-10-31 2021-03-26 中国科学院脑科学与智能技术卓越创新中心 KPNB1抑制剂和Bcl-xL抑制剂在制备抗肿瘤药物中的应用
CA3088253A1 (en) 2018-01-22 2019-07-25 Bioventures, Llc Bcl-2 proteins degraders for cancer treatment
CN109876145A (zh) * 2019-04-25 2019-06-14 中国科学院化学研究所 醋酸棉酚和化疗药的联合用药物
SG11202113356XA (en) 2019-06-12 2021-12-30 Juno Therapeutics Inc Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
WO2023107606A1 (en) 2021-12-09 2023-06-15 University Of Florida Research Foundation, Incorporated Bcl-xl/bcl-2 dual degraders for treatment of cancers
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806568A (en) * 1985-09-12 1989-02-21 Research Corporation Gossypol derivatives
US5026726A (en) * 1989-12-11 1991-06-25 The University Of New Mexico Gossylic iminolactones and gossylic lactones and their anti-viral activities
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method

Also Published As

Publication number Publication date
NZ529792A (en) 2007-04-27
EP1474121A2 (de) 2004-11-10
CA2449245A1 (en) 2002-12-05
WO2002097053A3 (en) 2004-09-10
ZA200309306B (de) 2006-07-26
NO20035301D0 (no) 2003-11-28
JP2005515158A (ja) 2005-05-26
IL159110A0 (en) 2004-06-01
EP1474121B1 (de) 2010-07-21
AU2002305769B2 (en) 2007-07-19
SG157952A1 (en) 2010-01-29
KR20040108528A (ko) 2004-12-24
ATE474568T1 (de) 2010-08-15
HK1071066A1 (en) 2005-07-08
US20030008924A1 (en) 2003-01-09
EP1474121A4 (de) 2006-05-03
CN1589135A (zh) 2005-03-02
WO2002097053A2 (en) 2002-12-05
ES2349349T3 (es) 2010-12-30
MXPA03010977A (es) 2005-04-08

Similar Documents

Publication Publication Date Title
ATE474568T1 (de) Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs.
BRPI0606891A2 (pt) anticorpos dr5 e usos dos mesmos
DE60201824D1 (de) Nahrungsergänzung zur behandlung von makula degeneration
PT1347971E (pt) Inibidores tiazolilicos de tirosina-cinases da familia tec
DE60031268D1 (de) Verfahren und zusammansetzung zur behandlung von krebs
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
ATE361084T1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
NO20060978L (no) Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
WO2001098317A3 (en) Alpha-glycosylceramides for treating bacterial and fungal infections
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
NO20082862L (no) Nye alkylfosfolipidderivater med redusert cytotoksisitet og anvendelse derav
ATE406884T1 (de) Zusammensetzungen mit pantothensäure oder derivaten davon und ihre verwendung zur stimulierung des appetits
DE60313434D1 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
ATE541855T1 (de) Weitere kristalline formen von rostafuroxin
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung
DE602004005821D1 (de) Enteralpräparat zur vorbeugung gegen bzw. behandlung von sepsis
EA200700413A1 (ru) Ариламинкетоны, способ их получения, фармацевтические композиции, содержащие их, и их применение
BRPI0411168A (pt) composição para o tratamento dos cabelos, usos de uma composição e método de tratamento dos cabelos
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat